The Challenge of Hemorrhagic Shock Management During Low-Molecular-Weight Heparin Treatment

Alessandro MorottiDepartment of Clinical and Biological Sciences, University of Turin, Orbassano, ItalyCorrespondence[email protected]

Enrica BrancaDepartment of Clinical and Biological Sciences, University of Turin, Orbassano, Italy

Angelo GuerrasioDepartment of Clinical and Biological Sciences, University of Turin, Orbassano, Italy

References

Dhakal P, Rayamajhi S, Verma V, et al. Reversal of anticoagulation and management of bleeding in patients on anticoagulants. Clin Appl Thromb Hemost. 2017;23(5):410–415. doi:10.1177/107602961667597027789605
PubMed Web of Science ®Google Scholar
van Veen JJ, Maclean RM, Hampton KK, et al. Protamine reversal of low molecular weight heparin: clinically effective? Blood Coagul Fibrinolysis. 2011;22(7):565–570. doi:10.1097/MBC.0b013e3283494b3c21959588
PubMed Web of Science ®Google Scholar
Wakefield TW, Andrews PC, Wrobleski SK, et al. Reversal of low-molecular-weight heparin anticoagulation by synthetic protamine analogues. J Surg Res. 1994;56(6):586–593. doi:10.1006/jsre.1994.10938015315
PubMed Web of Science ®Google Scholar
Sokolowska E, Kalaska B, Miklosz J, Mogielnicki A. The toxicology of heparin reversal with protamine: past, present and future. Expert Opin Drug Metab Toxicol. 2016;12(8):897–909. doi:10.1080/17425255.2016.119439527223896
PubMed Web of Science ®Google Scholar
Goodnough LT, Levy JH. The judicious use of recombinant factor VIIa. Semin Thromb Hemost. 2016;42(02):125–132. doi:10.1055/s-0035-156906826838698
PubMed Web of Science ®Google Scholar